Allergan Plc (AGN)

166.14
NYSE : Health Technology
Prev Close 166.35
Day Low/High 165.68 / 167.05
52 Wk Low/High 114.27 / 197.00
Avg Volume 4.92M
Exchange NYSE
Shares Outstanding 328.03M
Market Cap 54.57B
EPS -15.30
P/E Ratio N/A
Div & Yield 2.96 (1.77%)
Aegon Publishes 2018 Integrated Annual Report

Aegon Publishes 2018 Integrated Annual Report

Today, Aegon N.V.

CoolSculpting® And Sonja Morgan Partner To Talk Bikini Denial

CoolSculpting® And Sonja Morgan Partner To Talk Bikini Denial

-- Television Personality is Spokesperson for the World's #1 Nonsurgical Fat Reduction Treatment* --

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

In this day and age, companies must be 'disruptors' or get left in the dust.

Watching Shares of Och-Ziff Capital Management

Watching Shares of Och-Ziff Capital Management

With shares breaking above the recent, albeit small, pennant, there might be reason for optimism.

The 6 Stocks To Watch: Cramer's 'Mad Money' Recap (Thursday 3/7/19)

The 6 Stocks To Watch: Cramer's 'Mad Money' Recap (Thursday 3/7/19)

Jim Cramer's watching six stocks to determine when the selling will end.

Could Kroger Lose the Grocery Wars Over This Challenge?

Could Kroger Lose the Grocery Wars Over This Challenge?

Allergan is another stock that could stay stuck in its Doldrums. See which of its peers Jim Cramer likes better and why.

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

David Tepper's Appaloosa LP renews calls for changes at the top.

Allergan Rises After FDA Accepts License Applications for Botox Supplements

Allergan Rises After FDA Accepts License Applications for Botox Supplements

Allergan wants Botox licenses for pediatric patients.

Jim Cramer: No Room for Cynicism, JNJ's New Depression Drug Is Lifesaving

Jim Cramer: No Room for Cynicism, JNJ's New Depression Drug Is Lifesaving

The approval of esketamine, known as Spravato, for use against severe depression is special -- it is saving lives.

ALLERGAN 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Deadline In Class Action Lawsuit Against Allergan Plc. - AGN

ALLERGAN 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Deadline In Class Action Lawsuit Against Allergan Plc. - AGN

ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until February 19, 2019 to file lead plaintiff applications in a securities class action lawsuit against Allergan plc.

I Like These 2 Smaller Name Biotech Stocks

I Like These 2 Smaller Name Biotech Stocks

I still believe it will be a big year for buyouts across the biotech industry.

Aegon Reports Second Half 2018 Results

Aegon Reports Second Half 2018 Results

Net income declines to EUR 253 million reflecting unfavorable market movements and other charges Underlying earnings decrease by 8% to EUR 1,010 million, as lower Retirement Plans earnings in the US more than offset business growth and higher margins in...

Aegon To Grow Capital Generation And Dividends

Aegon To Grow Capital Generation And Dividends

Aegon has set new medium-term financial targets with a focus on growing capital generation and dividends.

Evolus Stockholders May Be Frowning in the Short Run

Evolus Stockholders May Be Frowning in the Short Run

Shares of the Botox competitor could correct/consolidate after a recent surge.

Don't Be A Hero: Cramer's 'Mad Money' Recap (Thursday 2/7/19)

Don't Be A Hero: Cramer's 'Mad Money' Recap (Thursday 2/7/19)

Don't get too bearish, says Jim Cramer, but don't break discipline here. This is a perfectly reasonable decline.

When Everyone Sees the Obvious the Obvious Rarely Happens

Right now it feels as though everyone sees the obvious resistance and overbought situation.

Botox Maker Allergan Falls After Tepper's Hedge Fund Challenges Management

Botox Maker Allergan Falls After Tepper's Hedge Fund Challenges Management

Shares of Botox maker Allergan slipped after a billionaire hedge-fund manager challenges the company's management.

Allergan Slides, Evolus Gains as FDA Approves Wrinkle Treatment to Rival Botox

Allergan Slides, Evolus Gains as FDA Approves Wrinkle Treatment to Rival Botox

Evolus surges Monday after the U.S. Food and Drug Administration approves the company's new wrinkle treatment for adult patients which is expected to be a key rival to Allergan's Botox.

ALLERGAN SHAREHOLDER ALERT: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Allergan Plc. - AGN

ALLERGAN SHAREHOLDER ALERT: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Allergan Plc. - AGN

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 19, 2019 to file lead plaintiff applications in a securities class action lawsuit against Allergan plc.

A Pharma Giant, an Airline and Other Stocks That Look Good Short

AGN, AVA, ALK, RLI and CRT all recently were downgraded by TheStreet's Quant Ratings.

How Are My Ideas Working Out? January Trade Review (Part 2)

How Are My Ideas Working Out? January Trade Review (Part 2)

Clearly, the first half of the month shaped up better than the second half.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALEX, CATS, EXTR, LAD Downgrades: AGN Initiations: LBC, MRBK, SBT Read on to get TheStreet Quant Ratings' detailed report:

What Boeing's Report Means for U.S. Companies With China Exposure

What Boeing's Report Means for U.S. Companies With China Exposure

Kate Warne, investment strategist at Edward Jones, talked to TheStreet about what Boeing's report means for U.S. companies with exposure to China, Apple's beat and how the healthcare sector is looking.

Allergan Tumbles After Swinging to Fourth-Quarter Loss

Allergan Tumbles After Swinging to Fourth-Quarter Loss

Botox maker reports a fourth-quarter loss of $4.3 billion, a reversal from a year-earlier profit of $3.05 billion.

Sloppy Earnings, China's Economy, AMD Earnings Preview: Market Recon

Sloppy Earnings, China's Economy, AMD Earnings Preview: Market Recon

What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.

Earnings Preview: Apple, AMD, Verizon, Other Giants to Report Crucial Q4

Earnings Preview: Apple, AMD, Verizon, Other Giants to Report Crucial Q4

Eight important companies report earnings between Monday and Tuesday. Don't miss them.

Allergan Could Retest Its December Low Before a Better Rally Attempt

Allergan Could Retest Its December Low Before a Better Rally Attempt

Allergan could move higher but some sort of retest of the December low seems in order in the short to intermediate term.

The Earnings Super Bowl: Cramer's 'Mad Money' Recap (Friday 1/25/19)

The Earnings Super Bowl: Cramer's 'Mad Money' Recap (Friday 1/25/19)

Jim Cramer's plan for getting through the heart of earnings season next week.

Jim Cramer: What Are We to Make of Today's Market Decline?

Jim Cramer: What Are We to Make of Today's Market Decline?

Is it a retest based on the damage the Fed has already done, the result of a breakdown in trade talks or a sign of a slowing global economy?

TheStreet Quant Rating: C (Hold)